These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19231912)

  • 1. First-year treatment patterns among new initiators of topical prostaglandin analogs.
    Schmier JK; Covert DW; Robin AL
    Curr Med Res Opin; 2009 Apr; 25(4):851-8. PubMed ID: 19231912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
    Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
    Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective.
    Schmier JK; Covert DW; Robin AL
    Curr Med Res Opin; 2007 Nov; 23(11):2867-75. PubMed ID: 17922980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G; Schwartz GF; Mozaffari E
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost.
    Covert D; Robin AL
    Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
    Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
    Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
    Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
    Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.
    Reardon G; Schwartz GF; Kotak S
    BMC Ophthalmol; 2010 Mar; 10():5. PubMed ID: 20196848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-year treatment costs among new initiators of topical prostaglandin analogs.
    Schmier JK; Covert DW; Robin AL
    Clin Ophthalmol; 2009; 3():637-44. PubMed ID: 19997567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
    Frenkel RE; Frenkel M; Toler A
    BMC Ophthalmol; 2007 Sep; 7():16. PubMed ID: 17900371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension.
    Heo JH; Rascati KL; Wilson JP; Lawson KA; Richards KM; Nair R
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1001-1010. PubMed ID: 31456491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of instillation methods for prostaglandin medications.
    Fiscella R; Wilensky JT; Chiang TH; Walt JG
    J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin analog treatment of glaucoma and ocular hypertension.
    Alexander CL; Miller SJ; Abel SR
    Ann Pharmacother; 2002 Mar; 36(3):504-11. PubMed ID: 11895065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.